Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Cytomegalovirus Disease

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...

Viral Recombination

Viral Recombination

Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Cirrhosis II: Pathophysiology

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Topical trichloroacetic acid versus electrocautery for treatment of anal intraepithelial neoplasia in people living with HIV: a multicentre, randomised, non-inferiority trial (TECAIN-study).

Infection·2026

Same author

Transjugular intrahepatic portosystemic shunt with ePTFE-covered stentgrafts: incidence and predictors of shunt dysfunction.

Insights into imaging·2025

Same author

German Registry Data Do not Adequately Reflect Reality.

Deutsches Arzteblatt international·2025

Same author

[Shortfalls of new data 2017-2020 in the German transplant registry].

Deutsche medizinische Wochenschrift (1946)·2024

Same author

Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.

Clinical and translational medicine·2024

Same author

[DRESS as a rare differential diagnosis in eosinophilia, skin rash and acute hepatitis].

Zeitschrift fur Gastroenterologie·2024

Search research articles

Related Experiment Video

Updated: Jul 18, 2026

A Protocol for Analyzing Hepatitis C Virus Replication

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Hepatitis C virus re-infection: new perspectives.

Martin F Sprinzl¹, Gerd Otto, Peter R Galle

¹Department of Internal Medicine, Johannes Gutenberg University Mainz, Mainz, Germany.

Clinical Transplantation

|November 15, 2006

Summary

Hepatitis C virus (HCV) re-infection impacts liver transplant outcomes. Current antiviral treatments show low efficacy, necessitating further research for improved patient prognosis after transplantation.

More Related Videos

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Related Experiment Videos

Last Updated: Jul 18, 2026

A Protocol for Analyzing Hepatitis C Virus Replication

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Area of Science:

Hepatology
Transplantation Immunology
Virology

Background:

Hepatitis C virus (HCV) re-infection is a major determinant of outcomes in liver transplant recipients.
Recurrent HCV cirrhosis leads to graft loss and is the primary cause of death post-transplantation.
Despite advances, the prognosis for HCV-infected patients undergoing liver transplantation has not improved in 20 years.

Purpose of the Study:

To highlight the critical role of HCV re-infection in liver transplant outcomes.
To discuss the challenges and limitations of current antiviral therapies for HCV recurrence.
To emphasize the need for optimized treatment strategies and further clinical trials.

Main Methods:

Review of existing literature on HCV re-infection post-liver transplantation.
Analysis of prognostic factors, including donor age and immunosuppression intensity.
Evaluation of the efficacy and toxicity of current antiviral treatments (interferon and ribavirin).

Main Results:

HCV re-infection significantly worsens graft survival and patient prognosis.
Increased liver donor age and intensified immunosuppression are linked to poorer outcomes.
Current antiviral regimens achieve low sustained viral response rates (10-30%).

Conclusions:

Effective management of HCV re-infection is crucial for liver transplant success.
Existing antiviral therapies are limited by toxicity and low efficacy.
Prospective trials are essential to determine optimal antiviral treatment timing and regimens for transplant patients.